Table 3.
Univariate and multiple regression analysis for the change of LVMI
| Variables | Univariate analysis | Multiple analysis | ||
|---|---|---|---|---|
| β (95% CI) | p value | β (95% CI) | p value | |
| Age | 0.05 (− 0.62 to 1.96) | 0.443 | ||
| Male | −2.98 (− 4.53 to 5.70) | 0.607 | ||
| Coronary artery disease | –3.54 (–8.22 to 3.98) | 0.896 | ||
| Hypertension | 0.28 (-0.96 to 1.84) | 0.279 | ||
| Baseline LV GLS | −1.80 (− 3.62 to 2.79) | 0.313 | ||
| Baseline LVMI | −2.68 (− 4.53 to − 1.89) | < 0.001 | −1.73 (− 3.53 to − 0.998) | < 0.001 |
| POAF | 2.73 (1.13 to 3.38) | < 0.001 | 1.46 (1.29 to 2.75) | < 0.001 |
| Postprocedural perivalvular leakage | –1.16 (–6.81 to 1.13) | 0.259 | ||
| ACE inhibitor/ARB | –1.07 (–3.16 to 1.35) | 0.458 | ||
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI, confidence interval; HR, hazard ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; POAF, postoperative atrial fibrillation. Postprocedural perivalvular leakage refers to the abnormal gap between the artificial heart valve ring and the patient’s own ring tissue after heart valve replacement, causing blood leakage through the gap